<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474953</url>
  </required_header>
  <id_info>
    <org_study_id>15PCHB</org_study_id>
    <nct_id>NCT02474953</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product</brief_title>
  <acronym>15PCHB</acronym>
  <official_title>A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Formulation to a Comparator Curcumin Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Biopharm, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating the pharmacokinetic profile (i.e. the way the product is&#xD;
      processed by the body) of a proprietary curcumin formulation compared to an unformulated&#xD;
      curcumin product. Subjects will take a single dose of either the proprietary formulation or&#xD;
      comparator product and the blood levels of curcumin and curcumin metabolites will be measured&#xD;
      over a period of 48 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Curcumin AUC</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
    <description>Area Under the Curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Curcumin Cmax</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
    <description>Maximum Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Curcumin Tmax</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
    <description>Time until maximum concentration</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood CBC levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood electrolyte levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood creatinine levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood AST levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood ALT levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood GGT levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in blood bilirubin levels</measure>
    <time_frame>Time 0 to 48 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dosing Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Proprietary Curcumin Formulation</intervention_name>
    <arm_group_label>Dosing Sequence 1</arm_group_label>
    <arm_group_label>Dosing Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Unformulated Comparator Curcumin Product</intervention_name>
    <arm_group_label>Dosing Sequence 1</arm_group_label>
    <arm_group_label>Dosing Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and females 18-45 years of age&#xD;
&#xD;
          2. If female, subject is not of child bearing potential, which is defined as females who&#xD;
             have had a hysterectomy or oophorectomy, bilateral tubal ligation or are&#xD;
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR&#xD;
&#xD;
             Females of childbearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives including oral contraceptives, hormone birth control&#xD;
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable&#xD;
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)&#xD;
&#xD;
               -  Double-barrier method&#xD;
&#xD;
               -  Non-hormonal intrauterine devices&#xD;
&#xD;
               -  Vasectomy of partner&#xD;
&#xD;
          3. BMI 18-29.9 kg/m2 (±1 kg/m2)&#xD;
&#xD;
          4. Healthy as determined by laboratory results and medical history&#xD;
&#xD;
          5. Agrees to maintain current level of physical activity throughout the study&#xD;
&#xD;
          6. Agree to avoid using black or white pepper, turmeric, curcumin or curry in the&#xD;
             preparation of food for 7 days prior to randomization and throughout the study period.&#xD;
&#xD;
          7. Agree to avoid Indian and Thai cuisines for the period of the study&#xD;
&#xD;
          8. Agree to avoid food with yellow dye #E100&#xD;
&#xD;
          9. Agrees to avoid alcohol, caffeine 12 hours and grapefruit and grapefruit juice 48&#xD;
             hours prior to baseline and each subsequent clinic visit&#xD;
&#xD;
         10. Agrees to consume only low polyphenols in the diet (nutritionists will counsel on high&#xD;
             polyphenol fruits, vegetables to avoid, wine, beer, supplements, herbal extracts, and&#xD;
             whole-grain based foods) 3 days prior to baseline and on test days (meal options and&#xD;
             lists of foods to avoid will be provided to subjects by nutritionists)&#xD;
&#xD;
         11. Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI ≥ 30 kg/m2&#xD;
&#xD;
          2. Women who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial.&#xD;
&#xD;
          3. Unstable medical conditions as determined by the Qualified Investigator&#xD;
&#xD;
          4. Use of natural health products containing turmeric or curcumin within 7 days prior to&#xD;
             randomization and during the course of the study&#xD;
&#xD;
          5. Use of St Johns Wort 3 weeks prior to baseline and during the study&#xD;
&#xD;
          6. Subjects who are smokers&#xD;
&#xD;
          7. Subjects with current or history of gastrointestinal problems or disease&#xD;
&#xD;
          8. Metabolic, endocrine, or chronic diseases&#xD;
&#xD;
          9. Immunocompromised individuals such as subjects that have undergone organ&#xD;
             transplantation or subjects diagnosed with human immunodeficiency virus (HIV)&#xD;
&#xD;
         10. Clinically significant abnormal lab results at screening (e.g. AST and/or ALT &gt; 2 x&#xD;
             ULN, and/or bilirubin &gt; 2 x ULN) will be assessed by the Qualified Investigator&#xD;
&#xD;
         11. Subjects who have planned surgery during the course of the trial&#xD;
&#xD;
         12. History of or current diagnosis of any cancer (except for successfully treated basal&#xD;
             cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer&#xD;
             in full remission more than 5 years of diagnosis are acceptable.&#xD;
&#xD;
         13. History of gallbladder issues, hyperacidity, gastric/duodenal ulcers.&#xD;
&#xD;
         14. Prior use of prescription H2 blocker, proton pump inhibitor or blood sugar-lowering&#xD;
             agents&#xD;
&#xD;
         15. Use of blood pressure medication&#xD;
&#xD;
         16. Subjects on restrictive dietary regimens&#xD;
&#xD;
         17. Blood donation in the last 2 months&#xD;
&#xD;
         18. History of blood/bleeding disorders or taking prescription blood thinners or&#xD;
             anti-platelet therapy&#xD;
&#xD;
         19. Alcohol abuse (&gt;2 standard alcoholic drinks per day) or drug abuse within the past 6&#xD;
             months&#xD;
&#xD;
         20. Use of medical marijuana&#xD;
&#xD;
         21. Clinically significant abnormal laboratory results at screening&#xD;
&#xD;
         22. Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
         23. Allergy or sensitivity to study supplement ingredients or to any food or beverage&#xD;
             provided during the study&#xD;
&#xD;
         24. Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
         25. Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

